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↑ What is "already known" in this topic: {#box1}
========================================

Previous studies have investigated the challenges of clinical trials only in the conducting step. Most of these studies reported challenges in developing countries.

→ What this article adds: {#box2}
=========================

This study provided a comprehensive review of the challenges of clinical trial studies in different steps including design, conducting, analysis, and reporting in both developing and developed countries.

Introduction {#s1}
============

Randomized clinical trials (RCTs) are considered as the gold standard for evaluating the effectiveness and safety of medical interventions ([@R1]). These types of studies are known as the basis for evidence-based decision making and the gold standard for clinical research. In recent years, a major scientific revolution to decide on evidence-based health care has led to the development of clinical trials ([@R2]). A well-conducted randomized clinical trial can be the most reliable method for measuring the effectiveness of clinical interventions ([@R3]).

Although clinical trial studies have been considered as the gold standard, the emphasis on the quality of these studies for their effects has always been taken into account. These studies are multidisciplinary and involve different steps, so they may face a variety of challenges that vary from one country to another.

One of the basic principles for conducting a clinical trial is that the collected data should be monitored; such regular monitoring helps to ensure that the risks to the participants are not more than expected and the study is done properly ([@R4]). Many universities have less awareness of the research priorities of clinical studies ([@R5]). Conducting these studies in developing countries often causes ethical, organizational, cultural, and infrastructural barriers for researchers, pharmaceutical companies, sponsors, and regulatory agencies ([@R2]).

Due to the unique social and economic conditions of India (low literacy, poverty, lack of public medical facilities) and the unique relationships between doctors and patients in this country, patients are exposed to the most vulnerable conditions in the process of clinical trials. The main concerns are related to the process of obtaining informed consent and compensation for participants due to injury or death ([@R6]). Patient recruitment is one of the main barriers to conducting these studies. Performing a trial of all medical expertise, issues on inequality, representation, and access to health care services may raise problems in patient recruitment, but the barriers to research partnerships for minorities are through the frameworks of cultural and therapeutic misconception, poor health literacy, lack of trust in the therapeutic system, or fear of relevance of the experiments ([@R7], [@R8]). Even if the costs of randomized clinical trials are comparable to the costs of standard care, lack of insurance coverage will prevent entry or registration ([@R6]).

The randomized clinical trials (RCTs) reviewed and published in leading journals are considered as the highest level of evidence in medicine. However, this is not always the case and RCTs, even when reported in these journals, can be misleading by 2 mechanisms: (1) timeliness or poor design in RCTs; (2) misinterpretation of even well-designed RCTs.

Several limitations may decrease the value of these studies: defects in patient selection, physician competence, randomization, applicability, endpoints, and the population being studied. Another problem with articles describing RCTs is the potential for the conclusions of the trial report to be misleading because of error or bias. This together with subsequent misinterpretation of the trial results or conclusions by others can make the effect of the trial misleading with an unintended detrimental result on medical practice ([@R9]).

Although the researcher may limit biasing through random allocation or blinding methods, clinical trial results may still be less acceptable ([@R3]).

Clinical trial studies have 4 steps of design, conducting, analysis, and reporting of results. Also, in these studies, different people are involved with different majors, which may result in some challenges associated with the conditions of each country. Therefore, the aim of this study was to‏ provide a comprehensive review of the challenges in conducting different steps of clinical trial studies (design, conducting, analysis, and reporting) in both developing and developed countries.

Methods {#s2}
=======

This systematic review was prepared and reported based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and flow diagram ([Fig. 1](#F1){ref-type="fig"}).
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All original articles presenting the barriers to clinical trial studies at one of the steps of design, conducting, analysis, and reporting of the results and meeting the inclusion and exclusion criteria have been included in this review.

Inclusion criteria {#s2-1}
------------------

-   Studies published in English

-   Studies published during 1991-2017

Exclusion criteria {#s2-2}
------------------

-   Studies that reported clinical challenges in the conducting of clinical trials in different areas of diseases.

Search strategy {#s2-3}
---------------

The search syntax was developed based on PubMed (Medline) and included 45 related keywords and was modified based on other international databases. Databases (Medline-PubMed, Embase, Web of Sciences, Scopus, and Google Scholar) were sought for relevant scientific evidence up to October 2017. The search strategy was limited to English articles published during 1991--2017 ([Table 1](#T1){ref-type="table"}).

###### Search strategy

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PubMed/Medline\
  ("clinical trial"\[tiab\] OR "Clinical study" \[tiab\] OR "Controlled clinical trial" \[tiab\] OR "randomized clinical trial"\[tiab\] OR "ran-domized controlled trial" \[tiab\] OR "Cross Over Design" \[tiab\] OR "Cross Over Studies" \[tiab\] OR "Crossover procedure" \[tiab\] OR \"Field Trial\"\[tiab\] OR RCTs\[tiab\] OR "Community Trial" \[tiab\] OR "Factorial Design" \[tiab\] OR "Cluster randomized design" \[tiab\] OR "Open trial" \[tiab\] OR "open study" \[tiab\] OR "Mega trial" \[tiab\] OR "Intervention Studies" \[tiab\] OR "interventional study" \[tiab\] OR "intervention trial" \[tiab\] OR "interventional studies" \[tiab\] OR "Pragmatic Clinical Trial" \[tiab\] OR "Zelen's design" \[tiab\] OR "Single Arm Trials" \[tiab\] OR "Parallel Group Design" \[tiab\] OR "parallel design" \[tiab\] OR "clinical epidemiology" \[tiab\]) AND (Barriers\[tiab\] OR Limitations\[tiab\] OR Problems\[tiab\] OR Chal-lenges\[tiab\] OR Difficulties\[tiab\] OR mistakes\[tiab\] OR set-back\[tiab\] OR hitch\[tiab\] OR trouble\[tiab\] OR hassle\[tiab\] OR Defects\[tiab\] OR Bugs\[tiab\] OR flaws\[tiab\] OR weaknesses\[tiab\] OR faults\[tiab\] OR restriction\[tiab\] OR imperfection\[tiab\] OR wrongs\[tiab\] OR blunders\[tiab\] ) AND 1991/01/01\[DP\]:2017/10/20\[DP\])

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Article screening and selection {#s2-4}
-------------------------------

In the first stage, titles and abstracts of all articles were evaluated by 2 researchers (FV, YM) independently. Then, full-texts were assessed to decide on relevancy of the articles. The researchers discussed the disagreement, if any, and in case an agreement was not reached, the third author (LJ) evaluated the study.

Quality Assessment {#s2-5}
------------------

The quality of each study was assessed according to Kuper . The criteria contain 6 major questions that address different key areas (design sample, data collection, analysis, reporting), each of which are answered as 'good', 'fair', and 'poor'. Based on the literature, a quality score was given for each question using the following definitions: Good: sufficient details are provided and well justified; fair: most information is given and justified but some information is missing; poor: no or few descriptive details are provided. The purpose of the quality assessment was not to establish thresholds to exclude the studies, but rather to distinguish between studies in overall contribution to the review .

Data extraction {#s2-6}
---------------

All papers included in the present study were evaluated independently by 2 researchers (FV, YM). They discussed the disagreements, if any, and in case an agreement was not reached, a third author (LJ) evaluated the study. A structured checklist was used to extract the data on the ([@R1]) name of first author and title, ([@R2]) country, ([@R3]) year of publication, ([@R4]) recommendations, ([@R5]) priority populations, ([@R6]) focus, and ([@R7]) outcomes. Additional information on the study results was extracted with respect to type of instruments.

Results {#s3}
=======

In the first step, 9637 studies were evaluated, of which 877 were duplicate articles and excluded. Then, 8760 remaining articles were evaluated based on their abstracts and 8688 irrelevant articles were excluded. In the next stage, full-texts were assessed and 43 articles were removed. Finally, after examining the studies and applying the inclusion and exclusion criteria, 29 studies remained and their results were evaluated. The following barriers in different steps of randomized clinical trials were identified: investigator-initiated trials may face similar difficulties with trials sponsored by international bodies. These difficulties will be related to handling of the regulatory bodies, administrative and financial bottlenecks, multiple languages, patient compensation options, interviewer compensation modalities, and additional documents required to facilitate data collection. Among the 4 stages of design, conducting, analysis, and reporting, the greatest challenges were related to conducting the randomized clinical trial. Challenges related to conducting were as follow: ethical and regulatory system obstacles ; financial bottle necks ; lack of skilled personnel ; barriers to patient recruitment ; lack of infrastructure ; lack of awareness and motivation ; lack of time ; lack of knowledge of the general population ; lack of knowledge among the research professionals ; lack of insurance coverage ; conflict of interest concerns ; lack of registry ; barriers to blinding ; issues in compensation calculation ; administrative bottle necks ; lack of integration between clinical trials and patient care ; lack of research environment ; lack of transparency ; lack of tools ; operational hurdle ; and multiple languages ‏. Other challenges were poor planning , lack of equipoise (design challenges), non-use of appropriate statistical methods for analysis (analysis challenges) and challenges related to reporting which include selective reporting , failure to report protocol , incomplete data reporting , and difficulty in clinical trial report ([Table 2](#T2){ref-type="table"}).

###### Barriers for designing, conducting, analyzing, and publish-ing clinical trials

  ------------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------- -----------------------------------------------------
  Barriers for designing, conducting, analyzing, and publishing clinical trials                                                                                                                    
  Thematic barriers                                                               Subthemes                                                      Reference                                         
  Barriers for designing a clinical trial                                         Poor design                                                    ([@R7], [@R20])                                   
                                                                                  Lack of equipoise                                              ([@R25], [@R31])                                  
                                                                                  Barriers for conducting a clinical trial                       Financial bottlenecks                             ([@R2], [@R5], [@R6], [@R14]-[@R16], [@R20]-[@R22])
                                                                                  Lack of insurance coverage                                     ([@R24], [@R26])                                  
                                                                                  Lack of knowledge among the research professionals             ([@R25], [@R26], [@R28])                          
                                                                                  Lack of knowledge among general public                         ([@R6], [@R24]-[@R27])                            
                                                                                  Ethical and regulatory system obstacles                        ([@R2], [@R5], [@R6], [@R13]-[@R19])              
                                                                                  Lack of skilled personnel                                      ([@R6], [@R14]-[@R16], [@R18], [@R21], [@R22])    
                                                                                  Lack of research environment                                   ([@R5])                                           
                                                                                  Lack of integration between clinical trials and patient care   ([@R20])                                          
                                                                                  Issues in compensation                                         ([@R2], [@R6])                                    
                                                                                  Lack of awareness and motivation                               ([@R6], [@R15], [@R16], [@R18], [@R27])           
                                                                                  Lack of tools                                                  ([@R20])                                          
                                                                                  transparency Lack of                                           ([@R17])                                          
                                                                                  Lack of infrastructure                                         (5[@R5], [@R6], [@R15], [@R16], [@R21], [@R22])   
                                                                                  Barriers to blinding                                           ([@R19], [@R30])                                  
                                                                                  Operational hurdles                                            ([@R15])                                          
                                                                                  Conflict of interest concerns                                  ([@R4], [@R25])                                   
                                                                                  Lack of registry                                               ([@R28], [@R29])                                  
                                                                                  Barriers to patient recruitment                                ([@R5]-[@R7], [@R23]-[@R26])                      
                                                                                  Multiple languages                                             ([@R2])                                           
                                                                                  Administrative bottlenecks                                     ([@R2], [@R18])                                   
                                                                                  Lack of time                                                   ([@R5], [@R14]-[@R16], [@R27])                    
  Barriers for analyzing a clinical trial                                         Lack of using appropriate statistical methods                  ([@R32])                                          
  Barriers for publishing a clinical trial                                        Selective reporting                                            ([@R3], [@R2])                                    
                                                                                  Incomplete reporting of data                                   ([@R17])                                          
                                                                                  Difficulty in clinical trial report                            ([@R29], [@R34])                                  
                                                                                  Failure to report protocol                                     ([@R27], [@R33])                                  
  ------------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------- -----------------------------------------------------

Discussion {#s4}
==========

As clinical trials usually affect patient care and management more than other types of studies do, it is highly important to consider the highest standards for writing, conducting, analyzing, and reporting these studies ([@R35]). In this study, the literature on barriers facing clinical trial studies in different steps (design, conducting, analysis, reporting) were reviewed. The greatest barriers were ethical and regulatory system obstacles, financial bottlenecks, lack of skilled personnel, and barriers to patient recruitment. In addition, several other challenges emerged from the research literature: lack of infrastructure, lack of awareness and motivation, lack of time, lack of knowledge among the general public, and lack of knowledge among the research professionals. By contrast, an article discussed the opportunities and challenges in conducting clinical trials globally. Informed consent, data quality, differences in medical practice, acceptability of foreign data, and ethical factors were global clinical trials challenges ([@R36]). A systematic review related to barriers for conducting clinical trials in developing countries indicated that the greatest challenge that researchers faced in developing countries was lack of financial and human capacity([@R37]). However, a systematic review on physician barriers in RCTs for cancer and other illnesses in the developed world identified lack of time as a major barrier ([@R38]). Another study discussed barriers to the conduct of randomized clinical trials within all disease areas. In that study, inadequate knowledge of clinical research and trial methodology, lack of funding, excessive monitoring, restrictive privacy law, lack of transparency, complex regulatory requirements, and inadequate infrastructures were barriers to randomized clinical trials ([@R39]).‏

Ethical and regulatory barriers were the most commonly cited reasons reported in the included studies. Developed countries perform a number of clinical trials in developing countries. In developing countries, such as India, these trials indicated that most Indians do not have access to good quality and affordable care and therefore may accept offers that might provide better quality and free treatment. They were conducted on people who were vulnerable because they could not afford good quality treatment or the most effective drugs ([@R6]). On the other hand, medications that are experimented in clinical trials in developed countries may not be used by people in developing countries due to their high cost. This subject can be an ethical problem because there is a principle in clinical trials that says the benefits of clinical trials must be more than their disadvantages and people should benefit from the result of these studies.

Another challenge was financial bottlenecks, which is reflective of the 10/90 gap in which less than 10% of health research funds in the world are directed toward problems that affect 90% of the world's population, and an even smaller percentage goes to fund researchers and health problems of developing countries ([@R6], [@R40], [@R41]). Funding for clinical trials in developing countries comes mostly from Western countries and the pharmaceutical companies based there ([@R42]). In most low-income countries, research is a luxury because of economic constraints ([@R43]). Scarce resources in developing countries are nearly all spent on program implementation, and allocating funds for research is almost out of the equation in most development plans. Contrary to existing beliefs and practices, the lack of resources in low- and middle-income countries paradoxically increases the need for reliable health care evidence to prioritize the use of these scarce resources ([@R44]).

Conducting clinical trials is essential for evaluating therapeutic interventions, but at the same time, taking care of patients is also of crucial importance. To address this necessity, numerous international statements and guidelines on protection of human subjects have been drafted and implemented. However, the results of a study conducted in India showed that in clinical research activity, because of the unique socioeconomic conditions in India (low literacy, poverty, general lack of medical facilities) and the unique doctor-patient relationship, the patient ends up being the most vulnerable in the clinical trial process. The culture and socioeconomic conditions of any country and region may affect the quality and the stages of conducting a clinical trial. The regulatory guidelines are part of a dynamic process and will continue evolving based on the changing requirements and demands of the system. Therefore, these regulations must be carried forward by proactively responding to such challenges with suitable clarifications and/or amendments without compromising the well-being of trial participants ([@R6]).

Conducting clinical trials and obtaining informed consent in any country are subject to the cultural conditions of that country. For example, the results of a study conducted in sub-Saharan Africa showed that the collection of blood samples from individuals in clinical trial projects could be challenging and may be one of the considerable reasons for local rumors of \"blood theft\" or \"blood sale\". Such attitudes and cultures could potentially have a profound effect on the success of research projects ([@R45]). Participants' knowledge is also highly important in properly implementing and collecting data of a clinical trial. To confirm these results, a study conducted in the United States showed that at least 40% of Americans did not understand the idea of a clinical trial.

For various reasons, knowledge can be a major factor in participation. First, low knowledge or confusion about the key facts of trial methods (random allocation, informed consent, standard treatment) can disrupt participation([@R46]) . Secondly, patients are often reluctant to participate in something about which they have little knowledge ([@R47]).

The lack of knowledge is not limited to patients. One of the most frequent probable reasons for the lack of reporting was lack of awareness and shortage of knowledge about clinical trials ([@R48], [@R49]). Prior to the conduction of trials, a protocol is conducted to specify the exact steps of the task. Due to the unpredictable nature of interventions in health sciences, some changes may occur during the implementation of the trials with respect to the approved protocols. Therefore, researchers need to include these changes in their reports ([@R50]). However, excessive defects of a protocol may result in patient damage and occurrence of errors in clinical trial outcomes. Although the CONSORT statement provides a comprehensive guide to protocol defect reports, the reports of studies are not complete. Hence, as the first step to improve reporting, authors are recommended to report protocol defects based on the CONSORT statement.

The results of the studies indicated that most researchers lacked knowledge and awareness even in the early definitions of the principles of a trial. For example, a study by Schulz et al showed that most researchers failed to recognize blinding and allocation concealment, and this suggested their lack of knowledge ([@R51]).

It is recommended that this issue be continually taught to researchers, as lack of knowledge may affect all stages of clinical trials and their outcomes. A study by White et al showed that knowledge rather than attitude is the leading factor impeding registration. Investigators were very unfamiliar with international registration tools other than clinicaltrials.gov ([@R28]).

Registration of clinical trials may prevent publication bias and selective reporting, as the bias caused by selective reporting can affect meta-analyses work on the results of systematic reviews and evidence-based studies, leading to giving incorrect answers to important clinical questions. Patients, doctors, and health policymakers rely on this information in their evidence-based decision‏ making ([@R3]). Thus, according to WHO, registration of a clinical trial is \"a scientific, ethical and moral responsibility\" ([@R52]). It is, therefore, highly important to promote the registration of clinical trials as part of the national research policy. However, a study conducted in Argentina showed that the current percentages of internationally registered trials and participants\' responses were insufficient to achieve the desired goals ([@R28]). It is important that all registrations, including integrated information elements, be electronically and widely searchable ([@R53]).

It should always be taken into consideration that clinical trial management is a public responsibility and requires a deep understanding of statistical methods.

This systematic review had limitations and strengths. It provided a comprehensive presentation of the challenges of clinical trial studies in different steps including design, conducting, analysis, and reporting, in both developing and developed countries. Because of the limited number of articles in the review, the study did not examine the similarities and differences between barriers among the different countries. Most of the included studies were qualitative. Those articles not written in English were excluded, as because the cost of translation was not feasible.

Conclusion {#s5}
==========

Among the 4 stages of design, conducting, analysis, and reporting, the most challenges were related to conduct of randomized clinical trial. The main barriers identified in the present systematic review were as follow: barriers related to handling ethical and regulatory systems, patient recruitment, lack of budget and skilled staff, lack of infrastructure, lack of knowledge among the general public, lack of awareness and motivation, and lack of time for conducting clinical trials. Barriers may vary widely depending on the context in which the clinical trials are conducted. There are several intercountry differences in culture, socioeconomic, and political contexts. Thus, findings of this review may not reflect the situation in any specific country. Providing training in different steps and levels to improve the quality of randomized clinical trial studies was the most important recommendation in these studies.
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